Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases

Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric antigen receptor (CAR) T-cell therapy experience treatment failure and subsequently have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a potentially curative approach for patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerhardt, Kristin, Jentzsch, Madlen, Georgi, Thomas, Sretenović, Aleksandra, Cross, Michael, Bach, Enrica, Monecke, Astrid, Leiblein, Sabine, Hoffmann, Sandra, Todorović, Milena, Bila, Jelena, Sabri, Osama, Schwind, Sebastian, Franke, Georg-Nikolaus, Platzbecker, Uwe, Vučinić, Vladan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481921/
https://www.ncbi.nlm.nih.gov/pubmed/34604075
http://dx.doi.org/10.3389/fonc.2021.737645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481921/
https://www.ncbi.nlm.nih.gov/pubmed/34604075
http://dx.doi.org/10.3389/fonc.2021.737645

Ejemplares similares